Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model

Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis...

Full description

Saved in:
Bibliographic Details
Published in:Turkish journal of haematology 2017-06, Vol.34 (2), p.137-142
Main Authors: Cengiz Seval, Güldane, Özkavukçu, Sinan, Seval, Murat, Aylı, Meltem
Format: Article
Language:English
Subjects:
Animals
chronic myeloid leukemia
Drinking water
Female
Females
Fertility
gonads
Laboratories
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Males
Mice
mouse
Neoplasms, Experimental - drug therapy
Neoplasms, Experimental - metabolism
Neoplasms, Experimental - pathology
nilotinib
Ovarian Follicle - metabolism
Ovarian Follicle - pathology
Pregnancy
Proteins
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Rodents
Spermatogenesis
Spermatogenesis - drug effects
Studies
Targeted cancer therapy
Tıp
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c513t-7b3a64f62f05f25ee7698afbf8384ed45b2fadbc7b5c922c5a97fe22172a42443
cites
container_end_page 142
container_issue 2
container_start_page 137
container_title Turkish journal of haematology
container_volume 34
creator Cengiz Seval, Güldane
Özkavukçu, Sinan
Seval, Murat
Aylı, Meltem
description Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters. Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months. When compared with the control group, a statistically significant decrease was demonstrated in the total follicle numbers of the female mice in the nilotinib group (268±110 vs. 170±60; p=0.03). Active spermatogenesis was observed in each tubule sample taken from the mice in the control and nilotinib groups. Spermatogenic activity was similar in the two groups. We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.
doi_str_mv 10.4274/tjh.2016.0092
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_839c270aeb734f51b7a2bb4e87b5a2a7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_839c270aeb734f51b7a2bb4e87b5a2a7</doaj_id><sourcerecordid>1921726391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-7b3a64f62f05f25ee7698afbf8384ed45b2fadbc7b5c922c5a97fe22172a42443</originalsourceid><addsrcrecordid>eNpVkk1v1DAQhiMEoqVw5Ioicegpi-PP-IJUbZey0i5cyg3JGjvjrpdsXJwE0X-P0y2F-mLL8_jRjPwWxduaLDhV_MO43y0oqeWCEE2fFac1I00lqGTP78-kUnmdFK-GYU8IbSQlL4uT_FBKzZrT4vtV7KGNY_wdXLnyHt04lNGXX0IXx9AHW4a-XO5S7HN9e4ddDG25wekHHgKU1wlhPGA_lpdxwBmFchunfNzGFrvXxQsP3YBvHvaz4tun1fXyc7X5erVeXmwqJ2o2VsoykNxL6onwVCAqqRvw1jes4dhyYamH1jplhdOUOgFaeaS0VhQ45ZydFeujt42wN7cpHCDdmQjB3F_EdGMgjcF1aBqmHVUE0CrGvaitAmotxybLgYLKro9H1-1kD9i6PFyC7on0aaUPO3MTfxnBOWmkyIL3D4IUf044jGYfp9Tn-U2t554l03Wmzo9UaBG62Hehx3_g-nJ1sTFca0UzWR1Jl-IwJPSPvdTEzBEwOQJmjoCZI5D5d_8P8Ej__XP2B4LMrOU</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1921726391</pqid></control><display><type>article</type><title>Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><source>DOAJ Directory of Open Access Journals</source><creator>Cengiz Seval, Güldane ; Özkavukçu, Sinan ; Seval, Murat ; Aylı, Meltem</creator><contributor>Küçükkaya,Reyhan</contributor><creatorcontrib>Cengiz Seval, Güldane ; Özkavukçu, Sinan ; Seval, Murat ; Aylı, Meltem ; Küçükkaya,Reyhan</creatorcontrib><description>Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters. Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months. When compared with the control group, a statistically significant decrease was demonstrated in the total follicle numbers of the female mice in the nilotinib group (268±110 vs. 170±60; p=0.03). Active spermatogenesis was observed in each tubule sample taken from the mice in the control and nilotinib groups. Spermatogenic activity was similar in the two groups. We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.</description><identifier>ISSN: 1300-7777</identifier><identifier>EISSN: 1308-5263</identifier><identifier>DOI: 10.4274/tjh.2016.0092</identifier><identifier>PMID: 27466938</identifier><language>eng</language><publisher>Turkey: Türk Hematoloji Derneği</publisher><subject>Animals ; chronic myeloid leukemia ; Drinking water ; Female ; Females ; Fertility ; gonads ; Laboratories ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Male ; Males ; Mice ; mouse ; Neoplasms, Experimental - drug therapy ; Neoplasms, Experimental - metabolism ; Neoplasms, Experimental - pathology ; nilotinib ; Ovarian Follicle - metabolism ; Ovarian Follicle - pathology ; Pregnancy ; Proteins ; Pyrimidines - adverse effects ; Pyrimidines - pharmacology ; Rodents ; Spermatogenesis ; Spermatogenesis - drug effects ; Studies ; Targeted cancer therapy ; Tıp</subject><ispartof>Turkish journal of haematology, 2017-06, Vol.34 (2), p.137-142</ispartof><rights>Copyright Galenos Yayinevi 2017</rights><rights>Copyright 2017 by Turkish Society of Hematology Turkish Journal of Hematology published by Galenos Publishing House. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-7b3a64f62f05f25ee7698afbf8384ed45b2fadbc7b5c922c5a97fe22172a42443</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1921726391/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1921726391?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27466938$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Küçükkaya,Reyhan</contributor><creatorcontrib>Cengiz Seval, Güldane</creatorcontrib><creatorcontrib>Özkavukçu, Sinan</creatorcontrib><creatorcontrib>Seval, Murat</creatorcontrib><creatorcontrib>Aylı, Meltem</creatorcontrib><title>Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model</title><title>Turkish journal of haematology</title><addtitle>Turk J Haematol</addtitle><description>Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters. Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months. When compared with the control group, a statistically significant decrease was demonstrated in the total follicle numbers of the female mice in the nilotinib group (268±110 vs. 170±60; p=0.03). Active spermatogenesis was observed in each tubule sample taken from the mice in the control and nilotinib groups. Spermatogenic activity was similar in the two groups. We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.</description><subject>Animals</subject><subject>chronic myeloid leukemia</subject><subject>Drinking water</subject><subject>Female</subject><subject>Females</subject><subject>Fertility</subject><subject>gonads</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Male</subject><subject>Males</subject><subject>Mice</subject><subject>mouse</subject><subject>Neoplasms, Experimental - drug therapy</subject><subject>Neoplasms, Experimental - metabolism</subject><subject>Neoplasms, Experimental - pathology</subject><subject>nilotinib</subject><subject>Ovarian Follicle - metabolism</subject><subject>Ovarian Follicle - pathology</subject><subject>Pregnancy</subject><subject>Proteins</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - pharmacology</subject><subject>Rodents</subject><subject>Spermatogenesis</subject><subject>Spermatogenesis - drug effects</subject><subject>Studies</subject><subject>Targeted cancer therapy</subject><subject>Tıp</subject><issn>1300-7777</issn><issn>1308-5263</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVkk1v1DAQhiMEoqVw5Ioicegpi-PP-IJUbZey0i5cyg3JGjvjrpdsXJwE0X-P0y2F-mLL8_jRjPwWxduaLDhV_MO43y0oqeWCEE2fFac1I00lqGTP78-kUnmdFK-GYU8IbSQlL4uT_FBKzZrT4vtV7KGNY_wdXLnyHt04lNGXX0IXx9AHW4a-XO5S7HN9e4ddDG25wekHHgKU1wlhPGA_lpdxwBmFchunfNzGFrvXxQsP3YBvHvaz4tun1fXyc7X5erVeXmwqJ2o2VsoykNxL6onwVCAqqRvw1jes4dhyYamH1jplhdOUOgFaeaS0VhQ45ZydFeujt42wN7cpHCDdmQjB3F_EdGMgjcF1aBqmHVUE0CrGvaitAmotxybLgYLKro9H1-1kD9i6PFyC7on0aaUPO3MTfxnBOWmkyIL3D4IUf044jGYfp9Tn-U2t554l03Wmzo9UaBG62Hehx3_g-nJ1sTFca0UzWR1Jl-IwJPSPvdTEzBEwOQJmjoCZI5D5d_8P8Ej__XP2B4LMrOU</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Cengiz Seval, Güldane</creator><creator>Özkavukçu, Sinan</creator><creator>Seval, Murat</creator><creator>Aylı, Meltem</creator><general>Türk Hematoloji Derneği</general><general>Galenos Publishing House</general><general>Galenos Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IEBAR</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20170601</creationdate><title>Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model</title><author>Cengiz Seval, Güldane ; Özkavukçu, Sinan ; Seval, Murat ; Aylı, Meltem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-7b3a64f62f05f25ee7698afbf8384ed45b2fadbc7b5c922c5a97fe22172a42443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>chronic myeloid leukemia</topic><topic>Drinking water</topic><topic>Female</topic><topic>Females</topic><topic>Fertility</topic><topic>gonads</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Male</topic><topic>Males</topic><topic>Mice</topic><topic>mouse</topic><topic>Neoplasms, Experimental - drug therapy</topic><topic>Neoplasms, Experimental - metabolism</topic><topic>Neoplasms, Experimental - pathology</topic><topic>nilotinib</topic><topic>Ovarian Follicle - metabolism</topic><topic>Ovarian Follicle - pathology</topic><topic>Pregnancy</topic><topic>Proteins</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - pharmacology</topic><topic>Rodents</topic><topic>Spermatogenesis</topic><topic>Spermatogenesis - drug effects</topic><topic>Studies</topic><topic>Targeted cancer therapy</topic><topic>Tıp</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cengiz Seval, Güldane</creatorcontrib><creatorcontrib>Özkavukçu, Sinan</creatorcontrib><creatorcontrib>Seval, Murat</creatorcontrib><creatorcontrib>Aylı, Meltem</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Idealonline online kütüphane - Journals</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Turkish journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cengiz Seval, Güldane</au><au>Özkavukçu, Sinan</au><au>Seval, Murat</au><au>Aylı, Meltem</au><au>Küçükkaya,Reyhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model</atitle><jtitle>Turkish journal of haematology</jtitle><addtitle>Turk J Haematol</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>34</volume><issue>2</issue><spage>137</spage><epage>142</epage><pages>137-142</pages><issn>1300-7777</issn><eissn>1308-5263</eissn><abstract>Tyrosine kinase inhibitors may have deleterious effects on spermatogenesis or folliculogenesis, resulting in male or female subfertility. The aim of this study is to determine the effect of nilotinib, which is used routinely to treat chronic myeloid leukemia, on spermatogenesis and folliculogenesis by using histopathological parameters. Ten male and ten female mice were orally treated with nilotinib at 20 mg/kg body weight dissolved in drinking water daily for 2 months. When compared with the control group, a statistically significant decrease was demonstrated in the total follicle numbers of the female mice in the nilotinib group (268±110 vs. 170±60; p=0.03). Active spermatogenesis was observed in each tubule sample taken from the mice in the control and nilotinib groups. Spermatogenic activity was similar in the two groups. We have demonstrated that even though spermatogenesis is preserved, folliculogenesis is inhibited by the usage of a continuous nilotinib treatment dose in chronic myeloid leukemia.</abstract><cop>Turkey</cop><pub>Türk Hematoloji Derneği</pub><pmid>27466938</pmid><doi>10.4274/tjh.2016.0092</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1300-7777
ispartof Turkish journal of haematology, 2017-06, Vol.34 (2), p.137-142
issn 1300-7777
1308-5263
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_839c270aeb734f51b7a2bb4e87b5a2a7
source PubMed (Medline); Publicly Available Content Database; DOAJ Directory of Open Access Journals
subjects Animals
chronic myeloid leukemia
Drinking water
Female
Females
Fertility
gonads
Laboratories
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
Male
Males
Mice
mouse
Neoplasms, Experimental - drug therapy
Neoplasms, Experimental - metabolism
Neoplasms, Experimental - pathology
nilotinib
Ovarian Follicle - metabolism
Ovarian Follicle - pathology
Pregnancy
Proteins
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Rodents
Spermatogenesis
Spermatogenesis - drug effects
Studies
Targeted cancer therapy
Tıp
title Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T23%3A07%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gonadotoxic%20Effects%20of%20Nilotinib%20in%20Chronic%20Myeloid%20Leukemia%20Treatment%20Dose%20in%20a%20Mouse%20Model&rft.jtitle=Turkish%20journal%20of%20haematology&rft.au=Cengiz%20Seval,%20G%C3%BCldane&rft.date=2017-06-01&rft.volume=34&rft.issue=2&rft.spage=137&rft.epage=142&rft.pages=137-142&rft.issn=1300-7777&rft.eissn=1308-5263&rft_id=info:doi/10.4274/tjh.2016.0092&rft_dat=%3Cproquest_doaj_%3E1921726391%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c513t-7b3a64f62f05f25ee7698afbf8384ed45b2fadbc7b5c922c5a97fe22172a42443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1921726391&rft_id=info:pmid/27466938&rfr_iscdi=true